The ‘cholinergic hypothesis of Alzheimer’s disease’ has accordingly directed the development of clinically approved acetylcholinesterase inhibitors that function to enhance available acetylcholine in synapses. The gene discussed is ACHE; the disease is early-onset autosomal dominant Alzheimer disease.